NEOS - Improvements At Neos Therapeutics Aren't Reflected In The Share Price

Neos Therapeutics (NEOS) stock has been lingering despite progress on multiple fronts. The company's drugs have displayed impressive revenue growth and perhaps even more impressive is the reduced cost, which has put the company on a path to profitability.

Here is an overview of their products, from the earnings deck:

The company has enjoyed enormous growth after launching their products, and in the last three years this has been accompanied by considerable operational improvements:

Data by YCharts

Most of the revenues come from their ADHD drugs, from the earnings deck:

Growth comes

Read more ...